INC Research's experience developing, implementing, and managing pregnancy registries is unsurpassed. We currently manage more pregnancy registries than any other CRO.
Below is contact information and links to our active pregnancy registry web sites for use by both patients and physicians.
Adenovirus Vaccine Pregnancy Registry
This is a prospective, observational, exposure-registration and follow-up study of pregnant women exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral and their live born offspring through the first year of life. Enrollment may be initiated by pregnant patients or health care providers of pregnant patients who received Adenovirus Type 4 and Type 7 Vaccine, Live, Oral while pregnant or who conceived within 6 weeks of vaccine administration. Please contact the Adenovirus Vaccine Pregnancy Registry via
Phone: 1.866.790.4549
Fax: 1.866.586.8406
Email: adenovirus@incresearch.com
Please reference http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM247515.pdffor package insert/prescribing information.
The Betaseron Pregnancy Registry, sponsored by Bayer HealthCare, is closed to enrollment and follow up.
http://www.cymbaltapregnancyregistry.com
Pregnant patients who have taken Cymbalta® at any time during pregnancy and their health care providers may contact The Cymbalta® Pregnancy Registry via:
Phone: 1-866-814-6975
Email: pregnancyregistries@incresearch.com
http://www.exenatidepregnancyregistry.com
Pregnant patients or health care providers of pregnant patients exposed to exenatide (BYETTA® injection or other formulations of exenatide) and/or one or more other non-insulin antidiabetic medications at the time of conception (i.e., on or after the first day of the last menstrual period) may contact the registry at:
Phone: 800-633-9081
Email: pregnancyregistries@incresearch.com
A Global Gleevec®/Glivec® & Tasigna® Pregnancy Exposure Registry
This is a voluntary, international, primarily prospective, observational, exposure-registration and follow-up study of women receiving Gleevec/Glivec or Tasigna during pregnancy or within six months prior to pregnancy.
Phone: 877-513-6684
Fax: 877-513-6682
Email: Novartis.20679@kendle.com
http://ribavirinpregnancyregistry.com
Phone: 800-593-2214
Fax: 800-800-1052
Email: pregnancyregistries@incresearch.com
The Savella Pregnancy Registry
http://www.savellapregnancyregistry.com
Pregnant patients exposed to Savella during pregnancy
Phone: 1- 877.643.3010
Fax : 1.800.800.1052
Email: pregnancyregistries@incresearch.com
Sumatriptan/Naratriptan/Treximet Pregnancy Registry
The Sumatriptan/Naratriptan/Treximet Pregnancy Registry, sponsored by GlaxoSmithKline, is closed to enrollment and follow up. To access the most recent registry report, please click on the link below, which will take you to the GlaxoSmithKline Sumatriptan/Naratriptan/Treximet Pregnancy Registry web page.
http://pregnancyregistry.gsk.com/sumatriptan.html
Pregnant patients or health care providers of pregnant patients who have been exposed to Keppra® or Keppra XR® prior to conception and during pregnancy may contact the UCB AED Pregnancy Registry (formerly, the Keppra Pregnancy Registry) via
Phone: 1-888-537-7734 (1-888-KEP-PREG)
Fax: 1-800-800-1052
Email: pregnancyregistries@incresearch.com
Please reference www.keppra.com for prescribing information.